IMAGINE
where you can go with ZILBRYSQ for GENERALIZED MYASTHENIA GRAVIS (gMG)

Discover the first FDA-approved, self-administered treatment for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

See ZILBRYSQ Results

Significantly improves gMG symptoms

In a clinical trial, people taking ZILBRYSQ experienced significant improvements in activities of daily living as measured by MG-ADL.*^†

SEE TRIAL RESULTS

Rapid improvements in daily living

In the 12-week clinical trial, patients taking ZILBRYSQ experienced significant improvement in activities of daily living such as breathing, talking, swallowing, and being able to rise from a chair.*^†

Some patients also saw improvements in gMG symptoms as early as Week 1.

gMG treatment in your hands

ZILBRYSQ is self-administered and can be injected in seconds, at home or on the go.

HOW TO TAKE ZILBRYSQ

MG-ADL=Myasthenia Gravis Activities of Daily Living.

*Individual results may vary, and not all people will experience improvements.

^†As determined by improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline on Week 12 of the study; -4.4 points in the ZILBRYSQ-treated group (86 people) vs -2.3 in the placebo group (88 people). Individual results may vary, and not all people taking ZILBRYSQ will experience improvements.

Here for you throughout your treatment

ONWARD™ provides personalized support, including financial options, tools to help you track your symptoms, refresher injection coaching, and guidance when starting and continuing treatment.

ONWARD is provided as a service of UCB and is intended to support the appropriate use of UCB medicines. ONWARD may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.

IMPORTANT SAFETY INFORMATION
INCLUDING BOXED WARNING

ZILBRYSQ is a medicine that affects part of your immune system. ZILBRYSQ may lower the ability of your immune system to fight certain infections. ZILBRYSQ increases your chance of getting serious and life-threatening meningococcal infections. You must complete meningococcal vaccines. Do not use ZILBRYSQ if you have a Neisseria meningitidis infection. ZILBRYSQ may also increase the risk of other types of serious infections. Pancreatitis and pancreatic cysts have happened in people who use ZILBRYSQ. The most common side effects of ZILBRYSQ include injection site reactions, upper respiratory tract infections, and diarrhea.

IMPORTANT SAFETY INFORMATION
INCLUDING BOXED WARNING

What is the most important information I should know about ZILBRYSQ?

ZILBRYSQ is a medicine that affects part of your immune system. ZILBRYSQ may lower the ability of your immune system to fight certain infections.

ZILBRYSQ increases your chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may become life-threatening or fatal if not recognized and treated early.
- You must complete or update two types of meningococcal vaccines (for both serogroup B infections and serogroup A, C, W, and Y infections) at least 2 weeks before your first dose of ZILBRYSQ if you have not already had these vaccines.
- If your healthcare provider decided that urgent treatment with ZILBRYSQ is needed, you should receive meningococcal vaccination(s) as soon as possible.
- If you have not completed or updated vaccinations for meningococcal infections at least 2 weeks before your first ZILBRYSQ dose and ZILBRYSQ therapy must be started right away, you must also receive antibiotics.
- If you had a meningococcal vaccine in the past, you might need additional vaccination before starting ZILBRYSQ. Your healthcare provider will decide if you need additional meningococcal vaccination.
- Meningococcal vaccines do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection:
  - headache with nausea or vomiting
  - headache and fever
  - headache with a stiff neck or stiff back
  - fever
  - fever and a rash
  - confusion
  - muscle aches with flu-like symptoms
  - eyes sensitive to light

Your healthcare provider will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 2 months after your last ZILBRYSQ dose. Your risk of meningococcal infection may continue for several weeks after your last dose of ZILBRYSQ. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.

ZILBRYSQ is only available through a program called the ZILBRYSQ REMS. Before you can receive ZILBRYSQ, your healthcare provider must:

enroll in the ZILBRYSQ REMS.
counsel you about the risk of meningococcal infection.
give you the Patient Guide, including information about the signs and symptoms of meningococcal infection.
give you a Patient Safety Card about your risk of meningococcal infection, as discussed above.
make sure that you are vaccinated with two types of meningococcal vaccines and, if needed, get revaccinated with the meningococcal vaccines. Ask your healthcare provider if you are not sure if you need to be revaccinated.

ZILBRYSQ may also increase the risk of other types of serious infections.

ZILBRYSQ may increase your chance of getting Streptococcus pneumoniae and Haemophilus influenzae type b. Your healthcare provider will tell you if you should receive the Streptococcus pneumoniae and Haemophilus influenzae type b vaccinations.
Certain people may have an increased risk of gonorrhea infection. Talk to your healthcare provider about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and about regular testing.

Call your healthcare provider right away if you have new signs or symptoms of infection.

Who should not use ZILBRYSQ?

Do not use ZILBRYSQ if you have a Neisseria meningitidis infection.

Before you use ZILBRYSQ, tell your healthcare provider about all of your medical conditions, including if you:

have an infection or fever.
are pregnant or plan to become pregnant. It is not known if ZILBRYSQ will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if ZILBRYSQ passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use ZILBRYSQ.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ZILBRYSQ?

ZILBRYSQ may cause serious side effects, including:

See “What is the most important information I should know about ZILBRYSQ?”
Inflammation of the pancreas (pancreatitis) and other pancreatic problems. Pancreatitis and pancreatic cysts have happened in people who use ZILBRYSQ. Your healthcare provider will do blood tests to check your pancreas before you start treatment with ZILBRYSQ.
- Call your healthcare provider right away if you have pain in your stomach area (abdomen) that will not go away. Your healthcare provider will tell you if you should stop using ZILBRYSQ. The pain may be severe or felt going from your abdomen to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis.

The most common side effects of ZILBRYSQ include:

injection site reactions.
upper respiratory tract infections.
diarrhea.

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ZILBRYSQ. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at www.fda.gov/medwatch or 1-800-FDA-10881-800-FDA-1088. You may also report side effects to UCB, Inc. by calling 1-844-599-CARE1-844-599-CARE [2273].

See the detailed Instructions for Use that comes with ZILBRYSQ for information on how to prepare and inject a dose of ZILBRYSQ, and how to properly throw away (dispose of) used ZILBRYSQ prefilled syringes.

INDICATION

What is ZILBRYSQ?

ZILBRYSQ is a prescription medicine used to treat adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
It is not known if ZILBRYSQ is safe and effective in children.

Please see the full Prescribing Information and Medication Guide for ZILBRYSQ, including the Boxed Warning regarding serious meningococcal infections. Please see the Instructions for Use for the ZILBRYSQ Single-Dose Prefilled Syringe. Talk to your healthcare provider about your condition or your treatment. For more information, go to www.ZILBRYSQ.com or call 1-844-599-22731-844-599-2273.